Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Diagnostic value of the γ-glutamyltransferase and alanine transaminase ratio, alpha-fetoprotein, and protein induced by vitamin K absence or antagonist II in hepatitis B virus-related hepatocellular carcinoma.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • معلومة اضافية
    • المصدر:
      Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE
    • بيانات النشر:
      Original Publication: London : Nature Publishing Group, copyright 2011-
    • الموضوع:
    • نبذة مختصرة :
      Hepatocellular carcinoma is a common type of malignancy with a poor prognosis. Identification and utilisation of markers for monitoring and diagnosis are urgently needed. Alpha-fetoprotein (AFP) and Protein Induced by Vitamin K Absence or Antagonist-II (PIVKA-II) have been proved to be efficient biomarkers for hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). The combination of the two markers could improve the detection rate. However, these indicators cannot meet the need of clinical diagnosis.It is necessary to discover novel serological markers and more cost-effective, appropriate combination of these markers for the diagnosis and surveillance of HBV-related HCC. Accordingly, in this study, we aimed to evaluate the diagnostic value of γ-glutamyltransferase (γ-GT) to alanine amino transferase (ALT) ratio alone or in combination with AFP and PIVKA-II for HBV-related HCC. 234 patients with HBV-related HCC and 396 patients with chronic hepatitis B (CHB) were enrolled in this study and approved by the institutional review board. Our results showed levels of AFP and PIVKA-II, and γ-GT/ALT ratio in cases with early-stage HCC, HCC, HCC plus HBV DNA positivity, and HCC plus HBV DNA negativity were higher than those in the corresponding CHB control group. Additionally, the levels of serum AFP and PIVKA-II, and the γ-GT/ALT ratio were positively correlated with tumour sizes in patients with HBV-related HCC. The areas under the ROC curves (AUROCs) of the γ-GT/ALT ratio in patients with early-stage HCC, HCC, HCC plus HBV DNA positivity, and HCC plus HBV DNA negativity were 0.795, 0.846,0.855, and 0.837, respectively; AUROCs of combination of the γ-GT/ALT ratio and PIVKA-II were 0.858, 0.928, 0.948, and 0.902, respectively; AUROCs of combination of the γ-GT/ALT ratio and AFP were 0.822, 0.886, 0.896, and 0.873, respectively;AUROCs of combination of the γ-GT/ALT ratio and PIVKA-II with AFP were 0.857, 0.928, 0.946, and 0.907, respectively, and AUROCs of combination of PIVKA-II and AFP were 0.804, 0.904, 0.942, and 0.863, respectively. In conclusion, the γ-GT/ALT ratio was a useful biomarker for the diagnosis of HBV-related HCC and that the combination of AFP and PIVKA-II with the γ-GT/ALT ratio could improve the diagnostic value of these biomarkers for HBV-related HCC. Moreover, the ratio of γ-GT/ALT may be a useful index in monitoring patients for progression of HBV-related HCC.
    • References:
      Zhonghua Gan Zang Bing Za Zhi. 2015 Dec;23(12):888-905. (PMID: 26739464)
      Surgery. 2013 Apr;153(4):510-7. (PMID: 23122930)
      World J Gastroenterol. 2015 Apr 7;21(13):3928-35. (PMID: 25852278)
      Hepatology. 2018 Jan;67(1):401-421. (PMID: 28859233)
      Medicine (Baltimore). 2017 Mar;96(11):e5811. (PMID: 28296720)
      BMC Cancer. 2017 Sep 1;17(1):608. (PMID: 28863782)
      Infect Agent Cancer. 2017 Aug 23;12:47. (PMID: 28852419)
      PLoS One. 2016 Apr 12;11(4):e0153227. (PMID: 27070780)
      CA Cancer J Clin. 2015 Mar;65(2):87-108. (PMID: 25651787)
      CA Cancer J Clin. 2018 Nov;68(6):394-424. (PMID: 30207593)
      J Gastrointest Cancer. 2017 Sep;48(3):238-240. (PMID: 28626852)
      Dig Dis. 2011;29(3):339-64. (PMID: 21829027)
      Gastroenterology. 2010 Feb;138(2):493-502. (PMID: 19852963)
      Dtsch Arztebl Int. 2014 Feb 14;111(7):101-6. (PMID: 24622679)
      Semin Cancer Biol. 2011 Feb;21(1):59-69. (PMID: 21144900)
      Lancet. 2018 Mar 31;391(10127):1301-1314. (PMID: 29307467)
      Tumour Biol. 2017 Jun;39(6):1010428317705763. (PMID: 28621228)
      Am J Gastroenterol. 2009 Sep;104(9):2182-8. (PMID: 19550411)
      CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90. (PMID: 21296855)
      Zhonghua Gan Zang Bing Za Zhi. 2019 Mar 20;27(3):236-240. (PMID: 30929345)
      Lancet. 2018 Apr 21;391(10130):1572. (PMID: 29695339)
      World J Gastroenterol. 2015 Oct 7;21(37):10573-83. (PMID: 26457017)
      Crit Rev Clin Lab Sci. 2001 Aug;38(4):263-355. (PMID: 11563810)
      Sci Rep. 2017 Aug 21;7(1):8954. (PMID: 28827721)
      CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32. (PMID: 26808342)
      Oncotarget. 2017 Oct 25;8(58):97758-97768. (PMID: 29228649)
      Oncology. 2010 Jul;78 Suppl 1:78-86. (PMID: 20616588)
      J Gastroenterol Hepatol. 2004 Mar;19(3):314-8. (PMID: 14748879)
      Chin J Cancer. 2014 Aug;33(8):388-94. (PMID: 25104174)
      Liver Cancer. 2012 Nov;1(3-4):141-3. (PMID: 24159578)
      Cell Physiol Biochem. 2014;34(3):903-15. (PMID: 25200250)
      J Clin Lab Anal. 2020 Feb;34(2):e23075. (PMID: 31659795)
      J Hepatol. 2015 Apr;62(4):848-54. (PMID: 25450201)
      Clin Chem. 2019 Dec;65(12):1543-1553. (PMID: 31672853)
      Cancer Lett. 2014 Apr 28;346(1):17-23. (PMID: 24374016)
      World J Gastroenterol. 2014 Sep 7;20(33):11684-99. (PMID: 25206273)
      Chin J Cancer. 2017 Aug 17;36(1):66. (PMID: 28818111)
      J Viral Hepat. 2002 Mar;9(2):128-33. (PMID: 11876795)
      Sci Rep. 2016 Oct 12;6:35050. (PMID: 27731353)
      World J Gastroenterol. 2019 Sep 28;25(36):5515-5529. (PMID: 31576097)
      PLoS One. 2011;6(8):e23077. (PMID: 21853071)
    • الرقم المعرف:
      0 (Biomarkers)
      0 (Protein Precursors)
      0 (alpha-Fetoproteins)
      53230-14-1 (acarboxyprothrombin)
      9001-26-7 (Prothrombin)
      EC 2.3.2.2 (gamma-Glutamyltransferase)
      EC 2.6.1.2 (Alanine Transaminase)
    • الموضوع:
      Date Created: 20200813 Date Completed: 20201221 Latest Revision: 20231112
    • الموضوع:
      20231112
    • الرقم المعرف:
      PMC7419311
    • الرقم المعرف:
      10.1038/s41598-020-70241-5
    • الرقم المعرف:
      32782270